Sun Pharma Of India Extends Deadline For Shares Of Israel’s Taro
This article was originally published in PharmAsia News
Executive Summary
India's Sun Pharmaceuticals has extended its offer for the shares of Israel's Taro Pharmaceuticals after failing to obtain all the shares by Oct. 3. The new deadline would be Sun's third for the firm, after encountering legal problems with the first one. The effort is a hostile takeover by Sun, which had a merger agreement with Taro earlier this year that fell apart. Sun already has 38 percent of Taro stock and is seeking to increase that to 48 percent, giving it 60 percent of voting rights and control of the Israeli firm. Legal issues involving the case are expected to be taken up by Dec. 15. (Click here for more
You may also be interested in...
Taro Rejects Sun Pharma’s Settlement Offer; Suggests Shareholder Referendum
MUMBAI - Israeli generic drug maker Taro has rejected Sun Pharma's proposal for a merger at a value of $9.50 per share or increase the offer price for non-promoter shares to $9 for every ordinary share. In a letter written to Sun Pharma's Chairman and Managing Director Dilip Shanghvi, Taro Chairman Barrie Levitt said the Taro board of directors "did not view the two options" set forth in the proposal as constructive or even "in the ballpark
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.